Cover Image
市場調查報告書

EpiCast Report:廣泛性焦慮症 (GAD) 的流行病學的預測 2024年

EpiCast Report: Generalized Anxiety Disorder - Epidemiology Forecast to 2024

出版商 GlobalData 商品編碼 345361
出版日期 內容資訊 英文 44 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:廣泛性焦慮症 (GAD) 的流行病學的預測 2024年 EpiCast Report: Generalized Anxiety Disorder - Epidemiology Forecast to 2024
出版日期: 2015年10月14日 內容資訊: 英文 44 Pages
簡介

主要8市場 (美國、法國、德國、義大利、西班牙、英國、日本及加拿大) 的廣泛性焦慮症 (GAD) 的12個月的患病病例總數,預計從2014年的1,368萬8,954件到2024年的1,434萬9,464件擴大4.8%,終生患病總數,從2014年的2,459萬4,259件增加到2024年的2,577萬599件4.8%。預計性別中女性比男性多,各年齡中以50-59歲為頂峰。

本報告提供全球主要8市場上廣泛性焦慮症 (GAD) 的患病病例數的轉變的相關調查、今後10年的預測、疾病的背景、風險要素和並存症、各年齡/性別/感染場所的診斷病例數、預測等相關彙整。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 風險要素與並存症
  • 全球趨勢
  • 預測手法
    • 使用來源
    • 未使用來源
    • 預測的前提條件、手法
  • GAD的12個月的患病病例數的流行病學預測
    • 患病病例數
    • 患病病例數:各年齡
    • 患病病例數:性別
    • 年齡調整比率
  • GAD的終生患病數的流行病學的預測
    • 終生患病數
    • 終生患病數:各年齡
    • 終生患病數:性別
    • 終生患病數:年齡調整比率
  • 檢驗
    • 流行病學預測的考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

  • 參考資料
  • 關於作者
  • 關於GlobalData
  • 關於EpiCast
  • 免責聲明

圖表

目錄
Product Code: GDHCER099-15

GAD is a common mental illness that is characterized by persistent and unrelenting worrying about everyday things such as personal finances, health, family, and work. GAD can be accompanied by one or all of the following physical symptoms: headache, fatigue, restlessness, edginess, and increased irritability. GAD is only diagnosed if the patient's worrying and anxiety present most days out of a week for at least six months in combination with one or more of the physical symptoms. The diagnosis of GAD must also be shown not to be directly related to any substance abuse disorder or general medical condition; it must not occur exclusively during an episodic mood disorder, psychotic disorder, or pervasive developmental disorder.

GlobalData epidemiologists forecast that the 12-month total prevalent cases of GAD in the 8MM will grow by 4.8% from 13,688,954 cases in 2014 to 14,349,464 in 2024 and lifetime total prevalence will grow by 4.8% from 24,594,259 cases in 2014 to 25,770,599 in 2024. GlobalData epidemiologists predict that GAD will affect more women than men with 69.35% of 12-month GAD and 66.04% of lifetime GAD found in women in 2014. GlobalData epidemiologists forecast that the prevalence of 12-month and lifetime GAD peaks in the age group 50-59 years, which contributed 23.57% of 12-month GAD and 23.54% of lifetime GAD in the 8MM in 2014.

GlobalData's epidemiological analysis provides a country-specific forecast for the diagnosed prevalent cases of GAD in the 8MM during 2014-2024. GlobalData's epidemiological forecast for the 12-month and lifetime total prevalent cases of GAD in the 8MM is supported by epidemiological data from country-specific studies, when available, which are nationally representative of the entire population of the respective market. This forecast is further strengthened by the use of uniform diagnostic criteria and methodology across each study that was included in the forecast. All countries for which data was found used the DSM-IV diagnostic criteria as well as the CIDI to estimate the total prevalence of GAD in each country. Each study used also presented a total prevalence rather than diagnosed, which gives a better estimate of the true burden of the disease as it will catch the undiagnosed cases of the disease.

Scope

  • The Generalized Anxiety Disorder (GAD) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for GAD in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Canada). It includes a 10-year epidemiological forecast of the one-year and lifetime prevalent cases of GAD segmented by sex, and age (in five-year increments beginning at 18 years and ending at =85 years) in these markets.
  • The GAD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM.

Reasons to buy

The GAD EpiCast series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global GAD market.
  • Quantify patient populations in the global GAD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for GAD therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast of 12-Month Total Prevalent Cases of GAD (2014-2024)
    • 3.5.1. 12-Month Total Prevalent Cases of GAD
    • 3.5.2. Age-Specific 12-Month Total Prevalent Cases
    • 3.5.3. Sex-Specific 12- Month Total Prevalent Cases
    • 3.5.4. Age-Standardized 12-Month Total Prevalent Cases
  • 3.6. Epidemiological Forecast of Lifetime Total Prevalent Cases of GAD (2012-2014)
    • 3.6.1. Lifetime Total Prevalent Cases of GAD
    • 3.6.2. Age-Specific Lifetime Total Prevalent Cases of GAD
    • 3.6.3. Sex-Specific Lifetime Total Prevalent Cases of GAD
    • 3.6.4. Age-Standardized Lifetime Prevalence of GAD
  • 3.7. Discussion
    • 3.7.1. Epidemiological Forecast Insight
    • 3.7.2. Limitations of the Analysis
    • 3.7.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for GAD
  • Table 2: 8MM, Sources Used to Forecast the 12-Month and Lifetime Total Prevalent Cases of GAD
  • Table 3: 8MM, 12-Month Total Prevalent Cases of GAD, Ages ≥18 Years, Both Sexes, N, 2014-2024
  • Table 4: 8MM, 12-Month Total Prevalent Cases of GAD, by Age, Both Sexes, N (Row %), 2014
  • Table 5: 8MM, 12-Month Total Prevalent Cases of GAD, by Sex, Ages ≥18 Years, N (Row %), 2014
  • Table 6: 8MM, Lifetime Total Prevalent Cases GAD, Ages ≥18 Years, Both Sexes, N, 2014-2024
  • Table 7: 8MM, Lifetime Total Prevalent Cases of GAD, by Age, Both Sexes, N (Row %), 2014
  • Table 8: 8MM, Lifetime Total Prevalent Cases of GAD, by Sex, Ages ≥18 Years, N (Row %), 2014

List of Figures

  • Figure 1: 8MM, 12-Month Total Prevalent Cases of GAD, Ages ≥18 Years, Both Sexes, N, 2014-2024
  • Figure 2: 8MM, 12-Month Total Prevalent Cases of GAD, by Age, Both Sexes, N, 2014
  • Figure 3: 8MM, 12-Month Total Prevalent Cases of GAD, by Sex, Ages ≥18 Years, N, 2014
  • Figure 4: 8MM, Age-Standardized 12-Month Total Prevalence (%) of GAD, by Sex, Ages ≥18 Years, 2014
  • Figure 5: 8MM, Lifetime Total Prevalent Cases GAD, Ages ≥18 Years, Both Sexes, N, 2014-2024
  • Figure 6: 8MM, Lifetime Total Prevalent Cases of GAD, by Age, Both Sexes, N, 2014
  • Figure 7: 8MM, Lifetime Total Prevalent Cases of GAD, by Sex, Ages ≥18 Years, N, 2014
  • Figure 8: 8MM, Age-Standardized Lifetime Total Prevalence (%) of GAD, by Sex, Ages ≥18 Years, 2014
Back to Top